单细胞组学在炎症性肠病中的研究:近期进展与未来临床应用
本文综述了单细胞组学技术(尤其是单细胞RNA测序)在溃疡性结肠炎和克罗恩病研究中的应用。该技术以单细胞分辨率揭示健康与炎症肠组织中免疫、上皮和基质细胞的改变,有助于发现新的细胞类型和功能,识别纤维狭窄、爬行脂肪、肛周瘘管和储袋炎等难治并发症的治疗靶点,并逐步用于理解治疗反应和药物失效机制。尽管尚处早期,这些研究为将新技术用于诊断、监测和预后预测的临床实践奠定了基础。
要点
- 单细胞组学可克服 bulk 转录组学 averaged 信号的局限,以单细胞分辨率揭示肠道多细胞组织的复杂性。
- 在健康与炎症肠组织中,单细胞组学有助于发现与疾病活动或并发症相关的新细胞类型和功能。
- 单细胞组学已逐步用于研究治疗反应、识别药物失效机制,并可能开发有临床实用价值的预测指标。
核心结论
- 单细胞组学研究为将新技术用于诊断、监测和疾病预后预测的临床实践奠定了基础,但作者指出目前仍处于早期阶段。
- 单细胞组学有助于识别纤维狭窄、爬行脂肪堆积、肛周瘘管或储袋炎症等难治并发症的治疗靶点。
- 单细胞组学已逐渐被用于研究治疗反应、识别药物失效机制,并可能开发有临床实用价值的预测指标。
研究设计与样本
- 本文为综述,旨在全面调查将单细胞组学应用于溃疡性结肠炎或克罗恩病研究的相关研究,并给出作者对主要发现的看法。
- 文章还讨论了将单细胞组学整合到临床实践和药物开发中的局限性和潜在益处。
主要发现
- 炎症性肠病(IBD)包括溃疡性结肠炎(UC)和克罗恩病(CD),是特征为肠道炎症的慢性疾病。
- 在这些疾病中,几乎所有肠道细胞类型的改变均有描述,包括免疫细胞、上皮细胞和基质细胞。
- IBD研究历史上依赖 bulk 转录组学,但该方法对多种细胞类型的信号取平均值,限制了洞察力。
- 单细胞组学技术克服了 bulk 分析的内在局限性,以单细胞分辨率揭示多细胞组织的复杂性。
- 在健康和炎症肠组织中,单细胞组学(尤其是单细胞RNA测序)有助于发现与疾病活动或并发症发展相关的新细胞类型和细胞功能。
临床怎么用
- 作者认为,这些研究为将新技术用于诊断、监测和疾病预后预测的临床实践奠定了基础,但指出目前仍处于早期阶段。
- 作者指出,单细胞组学已逐渐被用于研究治疗反应、识别药物失效机制,并可能开发有临床实用价值的预测指标。
局限性
- 作者指出,此类研究仍处于早期阶段。
- 作者在文中讨论了将单细胞组学整合到临床实践和药物开发中可能存在的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn's disease (CD), are chronic conditions characterised by inflammation of the intestinal tract. Alterations in virtually all intestinal cell types, including immune, epithelial and stromal cells, have been described in these diseases. The study of IBD has historically relied on bulk transcriptomics, but this method averages signals across diverse cell types, limiting insights. Single-cell omic technologies overcome the intrinsic limitations of bulk analysis and reveal the complexity of multicellular tissues at a cell-by-cell resolution. Within healthy and inflamed intestinal tissues, single-cell omics, particularly single-cell RNA sequencing, have contributed to uncovering novel cell types and cell functions linked to disease activity or the development of complications. Collectively, these results help identify therapeutic targets in difficult-to-treat complications such as fibrostenosis, creeping fat accumulation, perianal fistulae or inflammation of the pouch. More recently, single-cell omics have gradually been adopted in studies to understand therapeutic responses, identify mechanisms of drug failure and potentially develop predictors with clinical utility. Although these are early days, such studies lay the groundwork for the implementation in clinical practice of new technologies in diagnostics, monitoring and prediction of disease prognosis. With this review, we aim to provide a comprehensive survey of the studies that have applied single-cell omics to the study of UC or CD, and offer our perspective on the main findings these studies contribute. Finally, we discuss the limitations and potential benefits that the integration of single-cell omics into clinical practice and drug development could offer.
引用
- Gudiño V, Bartolomé-Casado R, Salas A, et al. Single-cell omics in inflammatory bowel disease: recent insights and future clinical applications. Gut. 2025. PMID: 39904604. doi:10.1136/gutjnl-2024-334165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。